

# Protection of Humans and Animals In Research



## Responsible Conduct of Research Series

---

Informed Consent and Vulnerable Population

Jill M. Baren, MD



## Goal

- “The goal of the informed consent process is to provide people with sufficient information so they can make informed choices about whether to begin or continue participation in clinical research.”

# Informed Consent **Process**



does not equal

# Informed Consent **Form**





# The process

- “...involves a dynamic and continuing exchange of information between the research team and participant throughout the research experience...”



# The document

- “...a starting point for the necessary exchange of information between investigator and potential participant.”
- “...the foundation not the entirety...”



## Why do we need it?

- Respect for persons
- Respect for autonomy of decision making
- True limit on investigative authority
- Sense of formality



**“It’s a very simple procedure. We slice off the top of your head, scoop out your innards with a spoon, and carve out your eyes and mouth.”**



# How do we get informed consent

- Varies according to study design and nature of participation
- Verbal vs. Written
- Investigator vs. proxy





# Informed Consent Regulations

DHHS:

45 CFR Parts 46.116 and 46.117

FDA:

21 CFR Parts 50.25 and 50.27








# Comprehension

- Consent not valid unless subject UNDERSTANDS
- Responsibility for understanding rests with RESEARCHER who must consider:
  - Nature of population
  - Type of information
  - Circumstances and timing
  - Language and culture



# General Requirements

-  Subject or legally authorized representative
-  Language understandable to subject
-  Allow subject to consider participation
-  Minimize coercion
-  Subject does not waive any legal rights



# IRB Responsibilities

- Set standards for consent documents
- Create templates
- Agree on “boilerplate language”
- Avoid legal interpretations and language
- Set limits on “marketing” tone
- Avoid jargon



# Actual Consent Statements

**“The risks associated with participating in this study are minimal, therefore there will be no compensation for injuries during this study”**

**“I understand that I may be unconscious and may not be able to consent.”**



# Actual Consent Statements

“If you are a woman who is having sex that could lead to pregnancy, you must agree not to become pregnant or make a woman pregnant.”

“We will insert 3 catheters, one in each arm.”



# Informed Consent Documentation

- Use only current IRB approved form
- Subject or legal representative must sign and date
- Provide subjects with copy of form
- Maintain documentation



# Investigator Responsibilities

- Train individuals obtaining consent
- Use technology or innovative approaches
- Be sensitive to subjects' needs
- Make adjustments in process, as needed
- Obtain IRB approval for changes





# Consent Process

- Typeface standards (font, point size)
- 6<sup>th</sup>-8<sup>th</sup> grade reading level
- Translation and/or interpretation
- “Witness” to signature or consent process
- Flowcharts or diagrams (IRB review)
- Video for information and portions of consent process (IRB review)



# EM research consent forms

- 94 forms from 96 EM programs performing research
- Mean years of education needed: 10
- Length and complexity increased with risk
- Average EM consent forms may be too difficult for the average participant to understand
- Mader TJ, Playe SJ: Annals of EM April 1997;29:534-539



# Informed consent gone wrong

- Jesse Gelsinger (gene transplant)
- James Quinn (artificial heart)
- Johns Hopkins (hexamethonium death)

# Gene therapy business: The tragic case of Jesse Gelsinger”



- 18 year old with partial ornithine transcarbamylase deficiency
- The first person to die from gene therapy



# Reactions

- FDA suspended all gene therapy trials and other experiments
- Hearings on quality of oversight and safety
- President Clinton demanded improvements in consent and access to information about gene therapy research

# James “Butch” Quinn: Artificial Heart Recipient



- 52 year old who received an artificial heart
- Lived for 10 months with the device
- Sustained fatal stroke



# Reactions

- Lawsuit over consent process
- Recipient's widow says she and her husband were misinformed and misled on risks, benefits and the potential for pain and suffering



## Volunteer in Asthma Study

- 24 hours after inhaling hexamethonium reported dry cough, shortness of breath, muscular aches and fever
- 2 days later admitted with concern for possible reaction
- Died one month later





# Reactions

- Research suspended
- Federal government temporarily shut down most research involving human subjects at the institution involved
- Hexamethonium not approved by the FDA and IRB did not provide adequate oversight



# Are we doing it right?

- Behaviors during informed consent (>1000 ED patients taking a survey)
  - 41% did not read
  - 57% who read spent < 60 seconds
  - 22% asked questions
  - 44% did not accept the form

Baren: AEM 2002



# Why do people participate?

- Altruism
- Free medical care and medications
- Trust
- Self-interest
- Attention
- Do we want to constrain people if they are doing things for the wrong reasons?



# Healthy volunteers

- May not benefit directly
- Could ultimately contribute to development of a new therapy
- Require particularly close monitoring
- Can pose risk to a volunteer's health or life



# Vulnerable populations

- Research on individuals who lack capacity requires prospect of benefit
- Not promulgated in federal regulations except in the case of children
- Family member can consent
  - If consistent with state law



# Vulnerable Populations

1. Children
2. Prisoners
3. Pregnant women/fetuses
4. Lactating women
5. Mentally disabled persons
6. Economically disadvantaged persons
7. Educationally disadvantaged persons



# Subtle considerations

- Language
- Culture
- Current Events or Incidents
- Age (elderly)
- Age (young)
- Cognitive Impairment
- Chemical Use
- Health Status
- Students
- Employees



# Vulnerable Populations: Children

- If child can understand (> age 6-8?)
  - We are obligated to obtain assent
- Limited form of decision making for children
- Promotes investment in the research





## Assent (45 CFR 46.408)

- Age
  - Maturity
  - Psychological state
- OR
- Direct benefit; intervention not otherwise available



## Documenting Assent and Permission (45 CFR 46.408)

- Permission document as per consent regulations
- Assent: IRB determines whether and how to document



# Assent/Permission

- Can parents overrule?
  - With possibility of benefit
- Studies with more than minimal risk?
  - Not without prospect of benefit



## One Parent or Two? (45 CFR 46.40)

- One Parent
  - < Minimal risk
  - > Minimal risk but direct benefit
- Both Parents, where possible
  - > Minimal risk, no direct benefit
  - Not otherwise approvable